Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
12.6 EUR | -2.33% | -5.26% | -8.03% |
05:04pm | J&J: encouraging results in the treatment of depression | CF |
03:01pm | Johnson & Johnson's Phase 3 Trial of Seltorexant to Treat Major Depressive Disorder Meets Primary, Secondary Endpoints | MT |
Turnover - Change in analysts' estimates
Earnings Per Share (EPS) - Change in analysts' estimates
EBIT - Change in analysts' estimates
Dividend / Share (DPS) - Change in analysts' estimates
Cash or Net Debt - Change in analysts' estimates
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Equities
- JNJ Stock
- JNJ0 Stock
- Revisions Johnson & Johnson